Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 5462

Next Previous
Drug Profile

AZD 5462

Alternative Names: AZD-5462

Latest Information Update: 06 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Heart failure therapies; Small molecules
  • Mechanism of Action RXFP1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heart failure

Most Recent Events

  • 10 Feb 2026 AstraZeneca completes the phase II LUMINARA trial in Heart failure (Treatment-experienced) in USA, Slovakia, Poland, Netherlands, Japan, India, Hungary, Denmark, Czech Republic, Bulgaria (PO) (NCT06299826)
  • 24 Sep 2025 AstraZeneca terminates a phase Ib clinical trials in Heart failure (Combination therapy, Adjunctive-treatment) in Bulgaria (PO) based on sponsor's decision (NCT06639087)
  • 28 Jul 2025 No recent reports of development identified for phase-I development in Heart-failure(In volunteers) in USA (PO, Liquid)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top